DENVER, Feb. 4 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG)
announced today that Kirk Calhoun has been appointed to the Company's Board of
Directors. Mr. Calhoun is a retired partner of Ernst and Young LLP and will
serve as chairman of the Audit Committee of the Board.
"We are extremely pleased that Kirk has agreed to join the Myogen Board of
Directors," stated J. William Freytag, President and CEO of Myogen. "His
extensive auditing and accounting background and experience with the
biotechnology industry provide him with keen ability to understand our
business from both a technical and financial perspective. We believe he will
be a great asset to the Company's Board and its stockholders."
Mr. Calhoun joined Ernst & Young LLP, a public accounting firm, in 1965
and served as a partner of the firm from 1975 until his retirement in 2002.
His responsibilities included both area management and serving clients in a
variety of industries, including biotechnology. Mr. Calhoun is a Certified
Public Accountant with a background in auditing and accounting. He has dealt
extensively with the Audit Committees and Board of Directors of his public
clients. He is currently on the Board of Directors of American Pharmaceutical
Partners, Inc. and the Board of Governors of the California State University
Foundation. Mr. Calhoun received a B.S. in Accounting from the University of
Southern California in 1965.
About Myogen
Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of small molecule therapeutics for the
treatment of cardiovascular disorders. Myogen currently markets one product
in Europe for the treatment of acute decompensated heart failure and has three
product candidates in late-stage clinical development: enoximone capsules for
the treatment of chronic heart failure, ambrisentan for the treatment of
pulmonary arterial hypertension and darusentan for the treatment of resistant
hypertension. The Company also conducts a target and drug discovery research
program focused on the development of disease-modifying drugs for the
treatment of chronic heart failure and related cardiovascular disorders.
Please visit our website at http://www.myogen.com .
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations,
+1-303-464-3986, derek.cole@myogen.com , or Joseph L. Turner,
Chief Financial Officer, +1-303-464-5222, joe.turner@myogen.com ,
both of Myogen, Inc.
|
